Eric Warren Purchases Shares in Mineralys Therapeutics

Eric Warren, the Chief Commercial Officer of Mineralys Therapeutics, Inc. (NasdaqGS: MLYS), recently purchased 104,124 shares of the company. The transaction, which took place on June 26, 2026, was valued at approximately $1.38 million, with shares bought at an average price of $13.24. This move was not part of a pre-planned trading scheme.

Insider Buying and Selling at Mineralys Therapeutics, Inc.

In addition to Eric Warren's recent purchase, Mineralys Therapeutics has seen other insider activity. On June 30, 2026, CEO Jon Congleton sold 75,000 shares at an average price of $26.14 as part of a planned transaction. Meanwhile, Chief Medical Officer David Malcom Rodman and Daphne Karydas also sold shares earlier in June.

Other Institutional Activity in Mineralys Therapeutics

Several institutional investors have adjusted their positions in Mineralys Therapeutics. Wellington Management Group significantly boosted its holdings by 2,574,801 shares, marking a 328.3% increase, ending with 3,359,068 shares worth about $90.9 million. RA Capital Management added 369,000 shares to reach 7,692,750 shares valued at $208.4 million, a 5.0% increase. FMR LLC trimmed its stake by 196,405 shares, a 3.9% decrease, holding 4,861,104 shares worth around $131.7 million. BlackRock, Inc. also increased its position by 153,904 shares, a 3.6% rise, resulting in a total of 4,481,582 shares valued at $121.4 million.

Mineralys Therapeutics, Inc. Stock Up 5.0%

Shares of Mineralys Therapeutics traded near $26.88 on Wednesday. The company, which focuses on developing medications for diseases driven by dysregulated aldosterone, has a market capitalization of roughly $2.35 billion. It currently has no meaningful P/E ratio as it isn't profitable, with a forward P/E of -12.73. The stock's 52-week range is between $12.59 and $47.65, with a 50-day moving average of $27.42 and a 200-day moving average of $32.88.

Analysts Set New Price Targets

Analysts are optimistic about Mineralys Therapeutics, with several maintaining a strong buy rating. B of A Securities kept its buy rating with a price target of $51 on March 13, 2026. Other firms like Stifel and HC Wainwright & Co. also maintained buy ratings with targets of $52 and $56, respectively. The consensus rating remains a strong buy, with a mean target price of $49 based on eight analyst opinions.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc. is a biopharmaceutical company headquartered in Radnor, Pennsylvania. It specializes in developing treatments for conditions caused by dysregulated aldosterone, such as hypertension and chronic kidney disease. The company is working on lorundrostat, an aldosterone synthase inhibitor. Led by CEO Dr. Jon Congleton, Mineralys employs 76 people and aims to address significant unmet medical needs in the cardiorenal space.

Bottom Line

Eric Warren's purchase of shares in Mineralys Therapeutics highlights insider confidence in the company's prospects. Investors often track such insider activity for potential insights into the company's health and future performance. However, it's important to remember that such filings are historical and may not reflect current positions. Analysts remain bullish on Mineralys, with strong buy ratings and competitive price targets.